Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MORDECAI N KLEIN

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1881629541
CMS profile
39469
Location
PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$460.10

12 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $460.10 12

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MORDECAI N KLEIN

NPI 1881629541 · CMS profile ID 39469

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1881629541?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MORDECAI N KLEIN, NPI 1881629541, CMS profile ID 39469. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881629541?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). MORDECAI N KLEIN, NPI 1881629541, CMS profile ID 39469. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881629541?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
MORDECAI N KLEIN, NPI 1881629541, CMS profile ID 39469, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–12 of 12 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1881629541?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

12 matching records · $460.10 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 12 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–12 of 12.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Abbott Laboratories $19.6410/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742515991 CMS
Abbott Laboratories $144.7410/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742536081 CMS
Abbott Laboratories $48.3709/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742504381 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $14.7309/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723097361 CMS
Abbott Laboratories $23.4608/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742534107 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $11.8207/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723097363 CMS
Abbott Laboratories $16.8707/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742533487 CMS
Abbott Laboratories $83.2406/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742531963 CMS
Abbott Laboratories $7.5003/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742518205 CMS
iRhythm Technologies, Inc. $22.4803/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750554833 CMS
Philips Electronics North America Corporation $56.2501/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751377569 CMS
Amgen Inc. $11.0001/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741423265 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $571.40 13
PY2020 $460.10 12
PY2021 $670.69 18
PY2022 $235.49 15
PY2023 $343.31 9
PY2024 $14.87 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $21,937.23 3
PY2024 Recipient $157,914.00 1
PY2024 Principal investigator $15,059.92 62
PY2023 Principal investigator $115,948.65 231
PY2022 Principal investigator $37,811.35 326
PY2021 Principal investigator $24,001.00 95

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

231 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043745
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043751
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043801
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043807
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043813
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043819
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043825
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,154.00 12/20/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043771
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,404.00 12/01/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043763
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043055
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043061
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043209
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043777
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043783
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043789
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043795
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,404.00 11/03/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043757
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 10/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041061
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 10/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041067
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 10/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041073
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041081
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041087
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041091
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041097
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041105
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041625
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041631
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041637
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041643
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043043
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043049
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043177
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043183
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043189
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043195
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043203
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040987
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040993
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040999
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041005
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041011
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041017
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041023
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041029
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041037
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 09/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041043
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 09/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041049
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 09/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041055
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 09/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042777
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042783
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042789
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 09/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042869
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042875
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042881
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042889
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042895
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042901
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,099.00 09/25/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043733
Principal investigator 1 Alnylam Pharmaceuticals Inc. $88.00 09/04/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042797
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 09/04/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042803
Principal investigator 1 Alnylam Pharmaceuticals Inc. $9.45 09/04/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042809
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 09/04/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042907
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040911
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040919
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040925
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040931
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040937
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040943
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040949
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040957
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040963
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 08/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040969
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 08/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040975
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 08/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040981
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042765
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042771
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042845
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042851
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042857
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042863
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,808.00 08/04/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043727
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040837
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040845
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040851
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040857
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040863
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040869
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040875
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040881
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040887
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 07/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040893
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 07/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040899
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 07/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040905
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042753
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042759
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042815
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042821
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042827
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042833
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997042839
Principal investigator 1 Alnylam Pharmaceuticals Inc. $11,154.00 07/17/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997043739
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040573
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040579
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040585
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040591
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040597
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040603
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040611
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040763
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040769
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040775
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040782
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040789
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040795
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040801
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040807
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040813
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 06/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040819
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 06/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040825
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 06/30/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040831
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040533
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040539
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040545
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040549
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040555
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040561
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040567
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040691
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040697
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040703
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040709
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040715
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040721
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040727
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040733
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040739
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 05/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040745
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 05/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040751
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 05/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040757
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,900.00 05/03/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997041265
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040459
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040465
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040495
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040501
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040509
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040515
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040521
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040527
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040615
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040621
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040629
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040635
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040641
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040647
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040653
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040659
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040665
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 04/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040671
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 04/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040677
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 04/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040683
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,500.00 04/12/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997041251
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,237.00 04/12/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997041259
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040151
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040157
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040163
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040169
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040175
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040181
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040187
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040193
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040371
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040377
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040385
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040391
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040397
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040403
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040409
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040415
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 03/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040421
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 03/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040427
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 03/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040433
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040441
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040447
Principal investigator 1 Alnylam Pharmaceuticals Inc. $67,592.00 03/01/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041239
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040101
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040107
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040113
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040119
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040125
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040131
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040137
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040143
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040293
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040299
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040305
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040311
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040317
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040323
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040329
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040335
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 02/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040341
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 02/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040347
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 02/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040353
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040359
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040365
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040051
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040059
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040065
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040071
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040077
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040083
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040089
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997040095
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040199
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040205
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040211
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040217
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040223
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040231
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040237
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040243
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040249
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040255
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040261
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040267
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 01/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040273
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 01/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040279
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 01/31/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997040285
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,500.00 01/23/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041227
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,375.00 01/23/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041233
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 01/23/2023 Non-covered Recipient Entity
Cedar Health Research, LLC
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997041245